Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07246564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

StatusRecruiting
PhasePhase 4
Started2025-12-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status, Contacts/Locations v11
Study sitesdetails revised at 1 of 12 sites
2026-05-21
Study Status, Contacts/Locations v10
Study sites11→12
2026-03-26
Study Status, Contacts/Locations v9
Study sites9→11
2026-03-12
Study Status, Contacts/Locations v8
Study sites8→9
2026-02-26
Study Status, Contacts/Locations v7
Study sites7→8
Show 6 earlier versions
2026-02-12
Study Status, Contacts/Locations v6
Study sites6→7
2026-01-29
Study Status, Contacts/Locations v5
Study sites5→6
2026-01-15
Study Status, Contacts/Locations v4
Study sites4→5
2026-01-05
Study Status, Contacts/Locations v3
Study sites3→4
2025-12-18
Study Status, Contacts/Locations v2
Study sites2→3
2025-12-09
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-12→confirmed 2025-12-01
Study sites0→2
2025-11-17
Original filing
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Trial Details
NCT Number NCT07246564
Lead Sponsor UCB Biopharma SRL
Conditions Myasthenia Gravis
Enrollment 40 participants
Start Date 2025-12-01
Primary Completion 2027-10-15 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-11